This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
このページの翻訳は実験的なもので、現在 開発中です。お待ちしております！
ALBO 株式概要
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders.
Albireo Pharma, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$44.15 |
| 52週高値 | US$45.23 |
| 52週安値 | US$16.02 |
| ベータ | 1.04 |
| 11ヶ月の変化 | -1.23% |
| 3ヶ月変化 | 85.66% |
| 1年変化 | 66.73% |
| 33年間の変化 | 98.69% |
| 5年間の変化 | 28.53% |
| IPOからの変化 | 202.40% |
最新ニュース
Recent updates
We're Hopeful That Albireo Pharma (NASDAQ:ALBO) Will Use Its Cash Wisely
Jan 02
Rock star Growth Puts Albireo Pharma (NASDAQ:ALBO) In A Position To Use Debt
Oct 25Albireo Pharma achieves positive phase 3 top-line results of Bylvay in Alagille syndrome
Oct 11Albireo Pharma: Assessing The Sagard Deal
Oct 03Albireo gains on royalty agreement for pruritus therapy
Sep 22Albireo gets reimbursed access to liver disease drug Bylvay in Italy
Sep 06These Analysts Just Made A Significant Downgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) EPS Forecasts
Aug 23Albireo Pharma GAAP EPS of -$2.04, revenue of $8.2M
Aug 15Albireo: The Commercialization Of Bylvay Is The Key To A Fair Valuation
Jul 22Despite Lacking Profits Albireo Pharma (NASDAQ:ALBO) Seems To Be On Top Of Its Debt
May 10Albireo: A Speculative Play With Upside
May 03Is Albireo Pharma (NASDAQ:ALBO) Using Debt Sensibly?
Feb 02Albireo: Successful And Accelerating Global Launch Drives Sales Revenue
Jan 31Albireo: Reasons For A Successful Transformation Into A Commercial Company
Nov 24Albireo Pharma: A Post Approval Assessment
Aug 09Albireo reports expanded data on Bylvay and A3907 at EASL international liver congress
Jun 21Some Shareholders May find It Hard To Increase Albireo Pharma, Inc.'s (NASDAQ:ALBO) CEO Compensation This Year
Jun 11Why Albireo Must Be Valued Higher Than Its Competitor Based On The Value Of Odevixibat
Apr 26Industry Analysts Just Made A Substantial Upgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) Revenue Forecasts
Feb 27Albireo launches late-stage trial of odevixibat in Alagille Syndrome
Dec 17Albireo submits U.S. and European applications for odevixibat in liver disease
Dec 09Albireo Pharma (ALBO) Investor Presentation - Slideshow
Nov 17Albireo Pharma's odevixibat shows durable response in a rare pediatric liver disease
Nov 13株主還元
| ALBO | US Biotechs | US 市場 | |
|---|---|---|---|
| 7D | 1.2% | -1.9% | 0.5% |
| 1Y | 66.7% | 10.4% | 20.5% |
業界別リターン: ALBO exceeded the US Biotechs industry which returned 6.8% over the past year.
リターン対市場: ALBO exceeded the US Market which returned -9.2% over the past year.
価格変動
| ALBO volatility | |
|---|---|
| ALBO Average Weekly Movement | 27.3% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.2% |
| 10% least volatile stocks in US Market | 2.8% |
安定した株価: ALBO's share price has been volatile over the past 3 months.
時間の経過による変動: ALBO's weekly volatility has increased from 17% to 27% over the past year.
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| n/a | 130 | Ron Cooper | www.albireopharma.com |
Albireo Pharma, Inc. 基礎のまとめ
| ALBO 基礎統計学 | |
|---|---|
| 時価総額 | US$921.13m |
| 収益（TTM） | -US$131.14m |
| 売上高(TTM) | US$57.39m |
16.1x
P/Sレシオ-7.0x
PER（株価収益率ALBO は割高か？
公正価値と評価分析を参照収益と収入
| ALBO 損益計算書（TTM） | |
|---|---|
| 収益 | US$57.39m |
| 売上原価 | US$2.55m |
| 売上総利益 | US$54.84m |
| その他の費用 | US$185.99m |
| 収益 | -US$131.14m |
直近の収益報告
Sep 30, 2022
次回決算日
該当なし
| 一株当たり利益（EPS） | -6.29 |
| グロス・マージン | 95.56% |
| 純利益率 | -228.51% |
| 有利子負債／自己資本比率 | 0% |
ALBO の長期的なパフォーマンスは？
過去の実績と比較を見る